Key Summary Points {#FPar1}
==================

Glucagon-like peptide 1 receptor agonists (GLP-1RA) are a potential treatment option for management of diabetes that could offset some of the increased cardiovascular risks associated with transplantationThere are only a few studies that have evaluated the safety and efficacy of GLP-1RA post transplantationWe hypothesized that GLP-1RA are safe and effective in managing diabetes in the transplant populationWe did a retrospective study looking at changes in immunosuppressant levels, HbA1c, and weight with the use of GLP-1RAOur study shows that GLP-1RA are safe and effective in the short term for the management of diabetes in solid organ recipients

Introduction {#Sec1}
============

Diabetes is one of the most significant comorbid conditions after solid organ transplantation. It is associated with long-term adverse effects in transplant recipients. Transplant patients may have pre-existing type 2 diabetes mellitus (T2DM) or develop diabetes after transplantation. Post-transplant diabetes mellitus (PTDM) is associated with reduced graft survival and increases cardiovascular disease-related morbidity and mortality in kidney, heart, and liver transplant recipients \[[@CR1], [@CR2]\]. Similarly, pre-existing diabetes increases the risk for graft loss and decreases survival in solid organ transplant (SOT) recipients \[[@CR3], [@CR4]\].

Management of diabetes after transplant poses specific barriers, such as potential interactions of antidiabetic medications with immunosuppressant medications as well as reduced renal function. In addition, fluid retention, weight gain, lactic acidosis, delayed gastric emptying, and negative effects on bone mass are all potential adverse effects that can affect the health of the transplant recipient.

Insulin is commonly used for the management of diabetes in transplant recipients, starting immediately post-operation when patients are usually on higher doses of steroids \[[@CR5]\]. Later, when the patients are on a more stable dose of steroids, other medications that are commonly used in the non-transplant population can be potentially used. However, options for non-insulin medications are limited because of several factors \[[@CR1]\]. Metformin poses a risk of lactic acidosis and cannot be used if renal function is reduced. Pioglitazone poses a risk of fluid retention and can worsen bone mineral density. Previous research has shown the safety and efficacy of dipeptidyl peptidase 4 (DPP4) inhibitors in this population \[[@CR6]\]. However, the efficacy of DPP4 inhibitors in glycemic control is limited and, in many situations, patients need a second agent.

Glucagon-like peptide 1 receptor agonists (GLP-1RA) are a relatively new class of diabetes medication that are commonly used for the management of T2DM in the non-transplant population. Besides glycemic control, they also have other potential advantages, such as weight loss and improved cardiovascular risk \[[@CR7]\]. GLP-1RA also carry a lower risk of hypoglycemia because they induce insulin secretion in a glucose-dependent manner. They can be used in patients with reduced renal function, and because GLP-1RA have weight-lowering benefits, they may be particularly useful to counteract the weight gain that typically occurs post-transplant. Furthermore, the reduction in HbA1c with GLP-1RA ranges from 0.8% to 2% \[[@CR8]\].

GLP-1RA are eliminated by proteolytic degradation. Therefore, their metabolism does not involve CYP- or transporter-mediated drug--drug interactions \[[@CR9]\]. Hence, they are theoretically safe because the chances of interaction with immunosuppressant medications are low. GLP-1RA are an attractive option for management of post-transplant diabetes, although only a small number of studies evaluated GLP-1RA for this condition \[[@CR10]--[@CR13]\].

In a study with 12 kidney transplant recipients and 12 controls, GLP-1RA infusion lowered fasting plasma glucose, reduced glucagon concentration, and increased first- and second-phase insulin secretion during a hyperglycemic clamp \[[@CR13]\]. In another small study, five patients who were treated with liraglutide post kidney transplant had improvement in glycemic control, weight, and had no adverse effects on graft renal function after a mean follow-up of 19 months \[[@CR10]\].

GLP-1RA delay gastric emptying and thus can affect the absorption of immunosuppressant medications \[[@CR14]\]. Data on the safety of GLP-1RA in the post-transplant population is also limited. In a small case series of five patients, co-administration of liraglutide with tacrolimus post kidney transplant did not clinically affect the trough tacrolimus levels \[[@CR11]\].

We hypothesized that GLP-1RA are safe and effective in the management of diabetes after transplantation.

Methods {#Sec2}
=======

We retrospectively analyzed kidney, heart, or liver transplantation recipients at the University of Nebraska Medical Center (UNMC) who had either pre-existing T2DM or developed PTDM and were subsequently treated with any of the available GLP-1RA: exenatide, liraglutide, dulaglutide, or semaglutide. Inclusion criteria were previous heart, kidney, or liver transplant, history of T2DM or PTDM, and use of any of the aforementioned GLP-1RA post transplantation. Exclusion criteria were age less than 19 years, type 1 diabetes mellitus (T1DM), and GLP-1RA use for less than 3 months.

The providers started their patients on a titrated GLP-1RA dose per the recommended protocol. Some patients did not reach the maximum dose. Baselines values were defined as the last measured values at, or within 1 month prior to, the time of starting GLP-1RA. Measurements taken included tacrolimus (FK506) levels, estimated glomerular filtration rate (eGFR), weight, body mass index (BMI), total cholesterol (TC), low-density lipoprotein (LDL), heart rate (HR), and liver function tests (LFT). The changes in these parameters were evaluated at 3, 6, and 12 months compared to baseline values using a paired *t* test. We also looked at all graft rejection episodes and mortality. Results are reported as mean difference (e.g., 3-month value − baseline value) with a 95% confidence interval of the difference. Descriptive statistics (counts, percentages, means, standard deviations, medians, and ranges) were used to summarize the data.

Three patients had known thyroid nodules. One patient had a previous thyroidectomy and pathology was benign, another patient had a benign biopsy, and the last patient had a biopsy but the results of that biopsy were not available. Two patients had ultrasounds without nodules reported. All other patients had a normal thyroid on physical exam and had no history of thyroid nodules/neoplasms.

The study was approved by UNMC Institutional Review Board (IRB) protocol \# 806-18-EP. Exemption to consent was approved by the IRB, since there was no or minimal risk to subjects because of the retrospective nature of the study. The study conformed with the Helsinki declaration of 1964, as revised in 2013, concerning human and animal rights.

Results {#Sec3}
=======

We identified 19 patients who fulfilled the inclusion and exclusion criteria. Sixteen patients had T2DM pre-transplant and three patients had PTDM. Baseline characteristics are listed in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristicsCharacteristicValueAge (years)62 (48--71)Sex  Male12 (63.2%)  Female7 (36.8%)Ethnicity  White13 (68.4%)  Black3 (15.8%)  Hispanic3 (15.8%)Organ  Kidney7 (36.8%)  Liver7 (36.8%)  Heart5 (26.3%)Family history of diabetes11 (57.8%)Weight (kg)104.78 (73.5--147.9)BMI (kg/m^2^)35.98 (26.96--46.78) Diabetes medication  Insulin17  Metformin3  DPP4i3  SGLT2i2  Sulfonylurea2HbA1c (%)8.0 (4.6--10.8)Data are presented as median (range) or count (percentage)*DPP4i* dipeptidyl peptidase 4 inhibitor, *SGLT2i* sodium/glucose cotransporter 2 inhibitor

The most common reason for kidney transplant was end-stage kidney disease due to hypertensive nephrosclerosis followed by diabetic nephropathy. Four patients had received a cadaveric transplant and three had received a living donor kidney. The most common reason for heart transplant was ischemic cardiomyopathy. Tacrolimus was used for immunosuppression in 18 out of 19 patients. Only one patient in our cohort was on cyclosporine. All heart and kidney transplant recipients were on mycophenolate, except for two kidney recipients because of BK viremia or BK virus-associated nephropathy. One of the liver transplant patients was on sirolimus. Five out of seven kidney transplant recipients were on maintenance steroids. One of the liver transplant recipients was on 1 mg of prednisone for systemic lupus erythematosus (SLE), otherwise all other liver and heart transplant recipients were not receiving steroids.

For management of diabetes, 17 patients were on insulin, out of which 15 were on basal--bolus regimen, one was on basal insulin only, and one was on prandial insulin only. Sixteen patients were on insulin analogues (glargine, lispro, and aspart) and one patient was on human insulin-U500 concentration. Five patients were on insulin in combination with oral medications. The mean total daily dose (TDD) of insulin at baseline was 77.11 units. At baseline, two patients were on oral medications only for diabetes management. Metformin and DPP4i were the most commonly used oral medications, followed by sulfonylurea and sodium/glucose cotransporter 2 inhibitors (SGLT2i). The most commonly used GLP-1RA was liraglutide (ten patients), followed by dulaglutide (five patients), and exenatide and semaglutide (two patients each). GLP-1RA were started after a median of 60 months after transplant.

FK506 levels did not show any significant change from baseline throughout the study period. There was no unexpected dose change of immunosuppressant medications during the study period. There was no significant change in renal function measured as eGFR during the 12 months of follow-up. There were no significant changes in LFTs. All safety endpoints are listed in Table [2](#Tab2){ref-type="table"}. There was one episode of rejection and mortality---a heart transplant recipient had acute rejection at 3 months after starting GLP-1RA, had multi-organ failure, and died. The authors are not able to decide if the rejection episode is related to GLP-1RA or not.Table 2Change from baseline of tacrolimus and renal functionVariablesChange from baseline to 3 monthsChange from baseline to 6 monthsChange from baseline to 12 monthsFK506 (ng/mL)0.36 (− 1.16, 1.88)0.27 (− 0.98, 1.53)0.82 (− 0.73, 2.36)eGFR (mL/min/1.73 m^2^)− 0.19 (− 3.55, 3.18)1.38 (− 0.76, 3.51)1.08 (− 1.63, 3.80)HR (bpm)6.63 (2.31, 10.96)4.94 (− 0.47, 10.36)3.62 (− 6.31, 13.54)Data are presented as mean (95% CI)*eGFR* estimated glomerular filtration rate, *HR* heart rate

Primary and secondary efficacy endpoints are listed in Table [3](#Tab3){ref-type="table"}. There was a statistically significant decrease in the mean weight and BMI between baseline and 3, 6, and 12 months. At the end of 12 months, there was mean drop in weight by 4.86 kg \[95% CI − 7.79, − 1.93\] and BMI decreased by a mean of 1.63 kg/m^2^ \[95% CI − 2.53, − 0.73\]. HbA1c decreased from baseline by 1.08% \[95% CI − 1.65, − 0.51\], 0.96% \[95% CI − 1.68, − 0.25\], and 0.75% \[95% CI − 1.55, 0.05\] at 3, 6, and 12 months, respectively. The mean TDD of insulin decreased from baseline by 12.06 units, 14.27 units, and 16.25 units at 3, 6, and 12 months, respectively. More than half the patients (57%) were able to decrease insulin requirements 1 year after starting GLP-1RA. Figure [1](#Fig1){ref-type="fig"} shows the spaghetti plot of individual variables for all subjects at different time points.Table 3Change of efficacy endpoints from baselineVariablesChange from baseline to 3 monthsChange from baseline to 6 monthsChange from baseline to 12 monthsWeight (kg)− 2.42 (− 3.88, − 0.96)− 2.84 (− 4.94, − 0.74)− 4.86 (− 7.79, − 1.93)BMI (kg/m^2^)− 0.89 (− 1.44, − 0.33)− 1.07 (− 1.85, − 0.29)− 1.63 (− 2.53, − 0.73)HbA1c (%)− 1.08 (− 1.65, − 0.51)− 0.96 (− 1.68, − 0.25)− 0.75 (− 1.55, 0.05)TDD of insulin (units)− 12.06 (− 21.95, − 2.17)− 14.27 (− 23.63, − 4.91)− 16.25 (− 33.32, 0.82)Total cholesterol (mg/dl)− 10.45 (− 32.22, 11.31)− 12.00 (− 41.53, 17.53)− 25.88 (− 44.28, − 7.47)LDL (mg/dl)− 18.64 (− 38.45, 1.18)7.42 (− 12.30, 11.30)− 20.63 (− 38.16, − 3.09)Data are presented as mean (95% CI)*BMI* body mass index, *HbA1c* hemoglobin A1c, *TDD* total daily dose, *LDL* low density lipoproteinFig. 1Spaghetti plot of**a**weight, **b**HbA1c, **c**HR, and **d**TDD of all subjects from baseline to 12 months. Median and range are given at each time point. *HR* heart rate, *TDD* total daily dose of insulin, *bpm* beats per minute

Two patients who were on combination of insulin and oral medications stopped oral medications after starting GLP-1RA. The use of oral medications decreased from 37% to 15%. Overall, 57% of patients were able to decrease the number of oral medications.

The most reported side effect was nausea in five patients. Three patients stopped the medication because of gastrointestinal (GI)-related adverse effects and two stopped because of cost (not covered by insurance or high co-pay). There were no reported incidents of severe hypoglycemia, pancreatitis, or malignancy, including thyroid cancers, during the follow-up period. There was a tendency towards an increase in heart rate, which was only statistically significant at 3 months. Heart rate increased by 6.6 bpm at 3 months and increased by 3.6 bpm at 12 months, but the increase at 12 months was not statistically significant.

Discussion {#Sec4}
==========

In SOT recipients, the choice of medication to treat comorbid conditions is significantly dependent on the interactions of drugs with immunosuppressants and other potential adverse effects that compromise the graft function. GLP-1RA can potentially slow gastric emptying and delay absorption. All subjects in our study were followed by our renal, cardiac, and liver transplant teams and had complete data on safety measures of FK506 levels, rejection episodes, medication changes, renal function, transaminases, and adverse effects. There were no differences in FK506 levels while on GLP-1RA in our cohort. Our results are similar to those of Pinelli et al. \[[@CR11]\], who reported a small case series of five patients that received co-administration of liraglutide with tacrolimus post kidney transplant; liraglutide did not clinically affect the trough tacrolimus levels. Singh et al. \[[@CR12]\] also reported in their study of dulaglutide in SOT recipients that the immunosuppressant regimen remained stable without any increased dose adjustment. This is in contrast to the Liou et al. \[[@CR10]\] study of five patients on liraglutide after kidney transplant, who reported that three patients could reduce the dose of tacrolimus and maintain optimal therapeutic levels. Renal function was also not affected in our cohort during the GLP-1RA use. The most common side effect to GLP-1RA reported in our study was nausea, which is commonly reported in the population of non-transplant patients who also take this class of medication. There were no other serious adverse effects noted in our study.

Our data shows that GLP-1RA improved glycemic control, with improvements in HbA1c (− 0.75%) and decreases in total daily dose of insulin (16.25 units) 12 months from baseline in SOT recipients. The number of oral medications decreased with GLP-1RA initiation, similar to results reported by Singh et al. \[[@CR12]\]. We saw reductions in weight and BMI in our cohort by a mean of 4.86 kg and 1.63 kg/m^2^, respectively, at the end of 12 months. Our results in weight and BMI reduction are higher than what has been previously reported by Singh et al.; however, this may be because the baseline BMI in our cohort was higher than the cohort in Singh et al.

The important difference in our study compared to earlier studies mentioned is that our cohort was on different GLP-1RA and not a particular agent, e.g., either dulaglutide or liraglutide. Our cohort also included an almost equal number of kidney, heart, and liver transplant recipients.

The current study was retrospective and thus there was no control group. In addition, the baseline values are single measurements prior to start of GLP-1RA, which may not reflect the true status prior to GLP-1RA start. Our cohort size is small and included three different organ transplant recipients and consequently different immunosuppressive regimens. This could have resulted in different effects on glucose metabolism. However, our cohort was on a stable immunosuppressive regimen and GLP-1RA was started after a mean of 60 months after the transplant. Therefore, these effects would have stayed the same or changed only minimally from before to after starting the GLP-1RA. Our study is unique as it is the first study to report on the use of multiple GLP-1RA in the transplant population.

Conclusions {#Sec5}
===========

Our study adds to the growing body of literature that the currently available GLP-1RA can be used for the management of post-transplant diabetes without affecting tacrolimus levels or transplant outcomes. Furthermore, SOT recipients taking GLP-1RA can expect similar glycemic and weight reduction effects as in the non-transplant population with diabetes.
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